Merrimack: ASCO GI 2015 (Merrimack) - Jul 18, 2015 - “MM-151 administered on a QW schedule demonstrated objective clinical activity at dose levels > 6 mg/kg with an acceptable safety profile and exposure levels in the expected therapeutic range. Initial results with MM-151 monotherapy on a Q2W schedule and in combination with irinotecan were similarly encouraging”; “An RP2D of 10.5mg/kg was defined for the QW monotherapy schedule and an expansion cohort in cetuximab-refractory CRC has been initiated. MM-151 dose escalation continues on the Q2W-mono and irinotecan combination schedules”; “Prolonged stable disease and radiographic responses (3 monotherapy and 3 combination therapy partial responses) were observed in heavily pre-treated solid tumor patients, including those with prior cetuximab therapy. Initial biomarker data suggests particular clinical benefit in triple-wildtype, EGFR-ligand positive CRC patients”
P1 data • Colorectal Cancer • Oncology
|